Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15978622 | 0.84 | CYP3A4 (0.41) | CYP3A4KEAP1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL2334297 | 0.83 | DPP4 (0.41) | KEAP1ALDH1A1DPP4ALOX15TSHR | |
| SCHEMBL21750024 | 0.81 | KEAP1 (0.45) | KEAP1HDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL30296903 | 0.79 | KEAP1 (0.44) | KEAP1HDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL7820374 | 0.79 | DPP4 (0.48) | ALDH1A1DPP4ALOX15TSHRCES2 | |
| SCHEMBL913406 | 0.79 | DPP4 (0.54) | CYP3A4KEAP1ALDH1A1POLBDPP4 | |
| SCHEMBL29469371 | 0.79 | DPP4 (0.54) | CYP3A4KEAP1ALDH1A1POLBDPP4 | |
| SCHEMBL670548 | 0.79 | KEAP1 (0.44) | KEAP1HDAC1HDAC6ALDH1A1POLB | |
| SCHEMBL29562833 | 0.78 | ABL1 (0.47) | HDAC1HDAC6ALDH1A1POLBALOX15 | |
| SCHEMBL1437701 | 0.78 | ABL1 (0.47) | HDAC1HDAC6ALDH1A1POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2780341-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Centaurus Biopharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265574-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | MAP3K20, MAP3K1, PRKCH | CYP3A4 4707/4885KEAP1 728/4885HDAC1 874/4885 |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | CYP3A4 2450/4885KEAP1 1389/4885HDAC1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.